Psyadon Pharmaceuticals, Inc.
On-Going Clinical Trials
Press Releases and News
Contact Us and Directions
Ecopipam is a selective antagonist of the D1 dopamine receptor. Its safety profile has been studied in over 1000 people.
Psyadon Pharmaceuticals is studying this drug for its ability to ameliorate multiple central nervous system diseases.